The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Alto Neuroscience Inc.’s ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients. Fast Track designation, an FDA process, expedites drug development for serious conditions with unmet medical needs. Eligible drugs...